This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.
Clinical Trial Updates on Treatments Targeting BRAF V600E in Metastatic Non-Small Cell Lung Cancer
This segment introduces the PHAROS trial design and rationale, describing how its dual-cohort structure and long follow-up provide foundational evidence for encorafenib + binimetinib in this rare population.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sarcopenia affects patients with ELD, ILD and pulmonary hypertension, new study shows
2
Optum Rx removes reauthorizations from an additional 40 drugs
3
FDA approves $2.59 million gene therapy for SMA
4
Orphan Drug Loophole Shields Blockbuster Drugs From Price Negotiations
5
